Lasmiditan

Phase 3

Eli Lilly and Company (LLY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Migraine

AXSMAXS-07 (meloxicam-rizatriptan)

Phase 3

AXSMAXS-07 (MoSEIC meloxicam and rizatriptan)

Phase 3

View Full Landscape

Drug Information

Target Indication

Migraine

Clinical Trial

NCT04396574

Last updated: 12/5/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/17/2022

Rayvow

RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

somatropin, rDNA origin, for injectionPhase 3

Growth Disorder

Ultra-Rapid LisproPhase 3

Type 1 Diabetes Mellitus

RetatrutidePhase 3

Obesity

Atomoxetine HydrochloridePhase 3

Attention Deficit Hyperactivity Disorder

LY2216684Phase 3

Major Depressive Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts